Karen Simeson has become the first person to receive the ‘antibody cocktail’ (Image: Sky News)
Get our daily coronavirus email newsletter with all the news you need to know direct to your inbox
Sign upWhen you subscribe we will use the information you provide to send you these newsletters. Sometimes they’ll include recommendations for other related newsletters or services we offer. OurPrivacy Noticeexplains more about how we use your data, and your rights. You can unsubscribe at any time.Thank you for subscribingWe have more newslettersShow meSee ourprivacy noticeInvalid Email
An intensive care nurse has become the first to receive a new "antibody cocktail" for people who cannot be vaccinated.
Karen Simeson said the injection, developed by British drugs firm AstraZeneca, "gives us some hope" that normality will soon return.
The treatment is meant for people who are cannot have the vaccine because they are already sick or are old and have a weakened immune system.
The jab will be administered to 1,000 people in the UK as part of a trial programme.
It has the potential to work immediately, offering protection from coronavirus for between six months and a year.
The treatment is meant for people who cannot be vaccinated
(Image: AFP via Getty Images)
Coronavirus cases still rising in 169 areas in England as full list shows worst hotspots
Mirror Politics newsletter – the e-mail you need to navigate a crisis-hit UK
Speaking after she received the injection in Wakefield, West Yorkshire, Karen told Sky News: "This treatment gives us some hope.
"I want that for everybody. I see how hard my colleagues are working on the frontline. We can't go out and have a laugh, there's no break for us.
"We all just want that normality back desperately and hopefully this can offer that."
She added that the NHS cannot rely on just one vaccine or treatment as a 'huge' number of people will require protection, meaning many different types of jabs will be needed.
The nurse has not seen her mum and dad since March and says she misses hugging her friends and girls.
She is desperate to return to normal life with her children.
The "antibody cocktail" differs from a vaccine as it introduces antibodies, rather than prompting the body's immune system to make them.
The aim of the trial is to evaluate the safety and effectiveness of a combination of two long-acting monoclonal antibodies – man-made proteins that act like natural human antibodies in the immune system.
Separately, AstraZeneca is developing a Covid-19 vaccine in conjunction with researchers at Oxford University.